Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics.

Published in:

Clinical Pharmacology in Drug Development, 2018, v. 7, n. 3, p. 233, doi. 10.1002/cpdd.422

By:

• Ye, Naidong;
• Monk, Scott A.;
• Daga, Pankaj;
• Bender, David M.;
• Rosen, Laura B.;
• Mullen, Jamie;
• Minkwitz, Margaret C.;
• Kugler, Alan R.

Publication type:

Article